Formulations containing Fab-PEG
A stable pharmaceutical composition for Fab-PEG or Fab'-PEG molecules is achieved by buffering between pH 5.0 and 7.0 with sucrose and glycine, ensuring long-term stability and rapid reconstitution.
Patent Information
- Application Number
- JP2024533010
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-01
- Filing Date
- 2022-11-30
- Publication Date
- 2024-11-15
AI Technical Summary
Existing pharmaceutical compositions containing Fab-PEG or Fab'-PEG molecules face stability issues during lyophilization and long-term storage, leading to aggregation and hydrolysis, with no universal protocol for formulating high concentrations of these molecules.
A pharmaceutical composition comprising Fab-PEG or Fab'-PEG molecules at concentrations of 50 to 200 mg/mL, buffered between pH 5.0 and 7.0, with 1 to 5% w/v sucrose, 0.5 to 4% w/v glycine, and optionally a surfactant, which is lyophilized to create a stable formulation.
The formulation achieves long-term stability and rapid reconstitution of Fab-PEG or Fab'-PEG molecules, minimizing aggregation and hydrolysis, with reconstitution times under 20 minutes and stability at 2-25°C for at least 12 months.
Smart Images

Figure 2024542784000001 
Figure 2024542784000002 
Figure 2024542784000003
Abstract
Description
[Technical field]
[0001] FIELD OF THEINVENTION The present invention relates to the field of pharmaceutical compositions. More specifically, the present invention relates to pharmaceutical compositions containing high concentrations of antibody molecules, more specifically Fab-PEG or Fab'-PEG molecules, and methods for making such pharmaceutical compositions. The pharmaceutical compositions according to the present invention can also be lyophilized to provide a lyophilized formulation. [Background technology]
[0002] 2. Background of the Invention The industrial production of therapeutic antibodies is a complex task. It requires scale-up from a laboratory-developed process for producing antibodies in milligram quantities to multi-kilogram quantities. Although antibodies are fairly stable molecules, they may still suffer from chemical and physical instability when stored at high concentrations for a period of time. Typical chemical instabilities may result in deamidation, hydrolysis, oxidation, beta-elimination, disulfide exchange, or reduction. Physical instability may result in denaturation, aggregation, or precipitation.
[0003] Although liquid formulations can be administered with minimal preparation, they have the disadvantage of decreasing stability over time.Stabilizing proteins in liquid formulations to avoid or minimize aggregation, precipitation, or degradation remains a special challenge.Aggregation, which involves the formation of insoluble matter or precipitate, is particularly problematic.It may cause immunological reactions upon administration and / or cause difficulties in carrying out proper administration of pharmaceutical compositions, for example, by causing blockage of delivery device.
[0004] Freeze-drying (i.e. lyophilisation) can be used for long-term storage stabilisation of antibodies that are otherwise unstable in liquid form. Freeze-drying of antibodies at lower temperatures reduces damage to the product and helps to preserve molecular integrity. It extends shelf life, reduces temperature requirements for transport and preserves the chemical and biological properties of the antibody. Freeze-drying facilitates achieving high concentrations of antibody in the final formulation, thus reducing injection volumes as well as injection times after reconstitution.
[0005] However, like other proteins, antibodies undergo denaturation upon lyophilization in the absence of stabilizers. Stabilizers may include certain sugars, polyols, amino acids, salts, and polymers, such as polyethylene glycol. Generally, a preferred stabilizer is selected for a given formulation, but in some cases, a combination of stabilizers may be used. The mechanism of stabilization upon drying is generally believed to be that the stabilizer functions as a water substitute. The interaction between water and proteins is believed to be important for the conformational stability of proteins. When water is removed upon drying, the stabilizer can form hydrogen bonds with the protein, as water molecules do, and may help retain the native protein structure during the lyophilization process (Chang L, et al. 2005).
[0006] The level of stabilization provided by sugars or polyols generally depends on their concentration. Increasing the sugar / polyol concentration to a certain level may eventually reach the limit of stabilization upon lyophilization or even destabilize the protein, and the specific ratio of stabilizer to protein may affect the storage stability of lyophilized antibodies (Chang L, et al. 2005). A crystalline bulking agent may function as a bulking agent, increasing the density of the solid product and minimizing structural loss. It also typically provides a uniform, dense composition and is generally easy to reconstitute. Glycine is another example of a bulking agent candidate in lyophilized products that require a crystallizable compound (Carpenter et al., 1997), and functions by providing the appropriate texture to avoid apparent volume and consistency challenges of the formulation, such as collapse during the initial drying process. Glycine has also been shown to potentially provide a small increase in stability in some circumstances (Meyer 2009), although conflicting data exist (WO2007124090).
[0007] WO2016128318 and WO2017194646 describe formulations containing full-length antibodies, sucrose, and glycine, among other stabilizer combinations. US6372716 describes a lyophilized formulation containing Factor IX in combination with glycine and sucrose.
[0008] WO2019096776 describes a spray-dried formulation containing a Fab-PEG molecule, a sugar (sucrose or trehalose), and at least one amino acid, such as glycine. However, the combination of sucrose and glycine did not show any promising results, at least from the perspective of reconstitution.
[0009] A significant challenge posed by Fab-PEG or Fab'-PEG molecules is their stability, particularly with respect to hydrolysis and ring-opening of the succinimide PEG linker, which leads to increased levels of acidic species.
[0010] Although lyophilization is a good choice to achieve the desired long-term storage of antibody molecules, there is no simple and versatile protocol to formulate antibody moieties such as Fab-PEG or Fab'-PEG molecules. These molecules may be unstable during the lyophilization process and / or long-term storage, aggregates may form upon reconstitution, or the lyophilized cake may take too long to reconstitute. High concentrations of stabilizers may affect the physicochemical properties (i.e., viscosity) of the final formulation. In view of the above, there remains a need in the art to provide further improved pharmaceutical compositions, more particularly lyophilized pharmaceutical compositions, that contain high concentrations of Fab-PEG or Fab'-PEG molecules. Summary of the Invention
[0011] SUMMARY OF THE PRESENT APPLICATION The present invention provides pharmaceutical compositions comprising a Fab-PEG or Fab'-PEG molecule at a concentration of about 50 to about 200 mg / mL, a buffer that maintains a pH between about 5.0 to about 7.0, about 1.0 to about 5.0% w / v sucrose, about 0.5 to about 4.0% w / v glycine, and optionally a surfactant. In some embodiments, the concentration of the buffer is about 10 to 50 mM.
[0012] In some embodiments, a pharmaceutical composition according to the invention comprises 100 mg / mL Fab-PEG or Fab'-PEG molecule, about 20 mM histidine buffer maintaining a pH of about 5.5, about 2.5% w / v sucrose, about 2.0% w / v glycine, and optionally about 0.05% w / v polysorbate 20.
[0013] Also provided herein is a lyophilized formulation obtained by lyophilizing any of the pharmaceutical compositions described herein. In some embodiments, the present invention provides a lyophilized formulation comprising about 50 to about 80% w / w Fab-PEG or Fab'-PEG molecules, about 3 to about 14% w / w buffer maintaining a pH between about 5.0 to about 7.0, about 7 to about 30% w / w sucrose, about 3.5 to about 24% w / w glycine, and optionally a surfactant.
[0014] In some embodiments, the Fab-PEG or Fab'-PEG molecule is derived from a humanized or human antibody. In some embodiments, the Fab-PEG or Fab'-PEG molecule specifically binds to CD40L.
[0015] The present invention also provides a method for making a lyophilized formulation, as well as a method for reconstituting a lyophilized formulation according to the present invention by adding a solvent, comprising the steps of: a. forming a mixture of Fab-PEG or Fab'-PEG molecules together with a buffer, sucrose, glycine, and an optional surfactant to obtain a pharmaceutical composition; b. subjecting the mixture of step a to lyophilization; and c. recovering the lyophilized formulation.
[0016] Also described is an article of manufacture comprising a container containing a pharmaceutical composition or lyophilized formulation according to the invention.
[0017] The pharmaceutical compositions and / or lyophilized formulations described herein may be useful for administration in the treatment of a disease or disorder.
[0018] definition The term "comprising" when used herein does not exclude other elements, i.e., it is to be interpreted as including all specifically mentioned features as well as any additional, unspecified features.
[0019] Where an indefinite or definite article is used when referring to a singular noun such as "a", "an" or "the", this includes a plural of that noun, unless otherwise stated.
[0020] The term "about" or "approximately" indicates an interval of accuracy that a person skilled in the art would understand to still ensure the technical effect of the feature in question. The term typically indicates a deviation of ±10%, preferably ±5% from the indicated numerical value. When the term "about" is used, the application also describes the use of the exact value specified. When referring to point values, the application also describes the approximation of such value used, the same for the end points of the range. For example, when the description specifies "about 50 to about 200", it means "50±10% to 200±10%" as well as "50 to 200".
[0021] The term "CD40L" or "CD40 ligand" refers to a protein also known as CD154, CD40 counterreceptor (CD40CR), gp39, T-BAM, T-cell activation molecule, TRAF, TNF-related activation protein (TRAP), and tumor necrosis factor ligand superfamily member 5 (TNFSF5). It is a 39 kDa type II membrane glycoprotein of the TNF family. CD40L is a 261 amino acid polypeptide consisting of a 215 amino acid extracellular domain, a 24 amino acid transmembrane region, and a 22 amino acid cytoplasmic tail.
[0022] The term "antibody" as used herein refers to monoclonal antibodies, and is not limited to recombinant antibodies made by recombinant techniques known in the art. "Antibody" includes any species of antibody having two essentially complete heavy chains and two essentially complete light chains, particularly mammalian species of antibody, human antibody of any isotype including IgA1, IgA2, IgD, IgG1, IgG2a, IgG2b, IgG3, IgG4, IgE and IgM, modified variants thereof, and / or antigen-binding fragments thereof.
[0023] The term "Fab" as used herein refers to an antibody fragment that contains one constant and one variable domain of the antibody heavy chain and one constant and one variable domain of the light chain. An "Fab'" molecule is a Fab that further contains a hinge domain.
[0024] The term "Fab-PEG" or "Fab'-PEG" refers to a molecule comprising a Fab or Fab' moiety, respectively, in combination with a PEG moiety. The Fab or Fab' molecule may comprise modified amino acid residues, such as cysteine or lysine residues, for pegylation. For example, a Fab molecule may be a modified Fab fragment, in which the modification is the addition of one or more amino acids to the C-terminus of its heavy chain that allows for the attachment of an effector molecule. The additional amino acids may form a modified hinge region containing one or more cysteine residues to which an effector molecule may be attached.
[0025] The Fab or Fab' portions can be obtained by culturing prokaryotic or eukaryotic host cells transfected with one or more expression vectors encoding the recombinant Fab or Fab' portions. For example, the eukaryotic host cells can be mammalian cells, such as Chinese Hamster Ovary (CHO) cells. Prokaryotic host cells are typically gram-negative bacteria, such as Escherichia coli (E. coli) cells. The host cells can be cultured in any medium that supports their growth and the expression of the recombinant proteins. The best conditions for each host cell are known to those skilled in the art.
[0026] Depending on the host cells used in the production, the Fab or Fab' portion can be purified after recovery from either the cell culture supernatant, the periplasmic space, or the inclusion bodies. Purification methods are well known to those skilled in the art. The purification methods typically involve a combination of various chromatographic and filtration steps. All steps are typically carried out in aqueous conditions. After the first series of purification steps, the Fab or Fab' portion can be PEGylated and further purified. The solution recovered at the end of the process can be subjected to formulation.
[0027] The term "PEG" refers to a poly(ethylene glycol) moiety. Other suitable PEG compounds include, but are not limited to, maleimide monomethoxy PEG, activated PEG polypropylene glycol, methoxy poly(ethylene glycol) polymers, but also the following types of charged or neutral polymers: dextran, colominic acid, or other carbohydrate-based polymers, polymers of amino acids, and biotin and other affinity reagent derivatives. The size of the PEG compounds can vary as desired, but generally ranges from an average molecular weight of 500 Da to 50,000 Da, e.g., 5,000 to 40,000 Da, such as 20,000 to 40,000 Da. The size of the polymer can be selected based on the intended use of the product, e.g., its ability to localize to certain tissues, e.g., tumors, or to extend circulating half-life (see Chapman, 2002). Thus, for example, where a product is intended to leave the circulation and penetrate tissues, for example for use in the treatment of tumors, it may be advantageous to use a low molecular weight polymer, for example having a molecular weight of approximately 5000 Da. In applications where the product will remain in the circulation, it may be advantageous to use a higher molecular weight polymer, for example having a molecular weight in the range of 20000 Da to 40000 Da.
[0028] The term "PEGylation" refers to the attachment, e.g., covalently, of a PEG moiety or derivative thereof to its partner molecule (e.g., a Fab or Fab' molecule) with or without derivatization with a coupling agent or coupling or activating moiety (e.g., with a thiol, triflate, tresylate, aziridine, oxirane, and / or maleimide moiety, e.g., PEG-maleimide). For example, a PEG moiety may be attached to a cysteine in the hinge region of a Fab' or modified Fab. Alternatively or additionally, a PEG-modified Fab fragment may have a maleimide group covalently linked to one thiol group in the modified hinge region. A lysine residue may be covalently linked to the maleimide group, and a methoxypoly(ethylene glycol) polymer having a molecular weight of approximately 20,000 Da may be attached to each of the amine groups on the lysine residues. Thus, the total molecular weight of the PEG attached to the Fab fragment may be approximately 40,000 Da. The best PEGylation methods are well known to those skilled in the art.
[0029] The terms "specifically bind to CD40L", "specifically bind to human CD40L" and equivalent descriptions, as used herein, mean that a Fab or Fab' molecule, pegylated or not, binds to CD40L / human CD40L with sufficient affinity and specificity to achieve a biologically meaningful effect. The selected molecule will usually have a binding affinity for CD40L / human CD40L, e.g., a Fab or Fab' molecule may bind to human CD40L with a Kd value between 100 nM and 1 pM. The term "Kd", as used herein, is intended to refer to the dissociation constant of a particular Fab or Fab' molecule-antigen interaction and represents the affinity of the Fab or Fab' molecule for its target. Affinity may be determined, for example, by surface plasmon resonance assays, such as BIAcore assays; enzyme-linked immunosorbent assays (ELISAs); and / or competitive assays (e.g., RIAs). Within the meaning of the present invention, a Fab or Fab' molecule that specifically binds to CD40L / human CD40L may also bind to another molecule, e.g., cyno CD40L. Fab or Fab' molecules that specifically bind to CD40L / human CD40L are also capable of neutralizing CD40L / human CD40L.
[0030] The term "neutralizing" as used herein refers to a Fab or Fab' molecule, pegylated or not, that inhibits or substantially reduces the biological effect of a molecule to which it specifically binds. Thus, the phrase "a Fab or Fab' molecule neutralizes CD40L / human CD40L" refers to a Fab or Fab' molecule that specifically binds to CD40L or human CD40L and inhibits or substantially reduces its biological effect, for example, by blocking binding of CD40L to CD40.
[0031] The term "high concentration" or related terms in the context of a Fab or Fab' molecule, whether PEGylated or not, means that the concentration of the molecule is at least 50 mg / mL.
[0032] The term "stability" as used herein refers to the physical, chemical, and conformational stability of the PEGylated or non-PEGylated Fab or Fab' molecules in the formulation according to the invention. Instability of protein formulations can be caused, for example, by chemical degradation or aggregation of the protein to form higher order polymers, deglycosylation, glycosylation, or oxidative modifications.
[0033] The term "stable formulation" refers to a formulation in which the protein of interest (here, a Fab or Fab' molecule, PEGylated or not) essentially retains its physical, chemical and / or biological properties upon storage. A variety of analytical methods are well within the knowledge of one of skill in the art to measure protein stability in a formulation (see several examples in the Examples section). Stability is typically assessed at a selected temperature (e.g., -70°C, 2-8°C, 25°C, or 35°C or higher) over a selected period of time (e.g., 3 months, 6 months, or 12 months or more). Because Fab or Fab' molecules (PEGylated or not), once formulated, are typically stored in a refrigerator (typically 2-8°C) or at room temperature (typically 15-25°C) before being administered to a patient, it is important that the formulated molecule is stable over a period of time that is at least 2-25°C, as illustrated by, for example, 2-8°C and 25°C. To characterize the stability over a given period of time (relative to initial data), various values can be used, for example (but not limited to): 1) no more than 10% change per year in the monomeric form of the antibody if storage is performed at 25° C.; 2) no more than about 0.5 points / year (0.5% per year) change in high molecular weight species (HMW or HMWS; also referred to herein as aggregates) if storage is performed at 2-8° C., or no more than about 3 points / year (3% per year) change in HMWS if storage is performed at 25° C.; and / or 3) no more than + / - 0.3 units of variation in pH.
[0034] As used herein, a "pharmaceutical composition" can also be referred to, without any distinction, as a "stable pharmaceutical composition," a "formulation," or a "stable formulation."
[0035] The term "buffer" as used herein refers to a solution of a compound that is known to be safe in formulations for pharmaceutical or veterinary use and that acts to maintain or control the pH of the formulation within a desired pH range for the formulation.
[0036] The term "surfactant" as used herein refers to a soluble compound that can be used specifically to improve the water solubility of hydrophobic oily substances or to improve the miscibility of two substances with different hydrophobicities. For this reason, these polymers are usually used in industrial applications, cosmetics, and pharmaceuticals. They are also used as model systems for drug delivery applications, especially to modify the absorption of drugs or their delivery to target tissues. Well-known surfactants include polysorbates (polyoxyethylene derivatives also known as Tweens; such as PS20 or PS80) and poloxamers (i.e., copolymers based on ethylene oxide and propylene oxide, also known as Pluronics®).
[0037] The term "stabilizer", "stabilizing agent" or "isotonic agent" as used herein is a compound that is physiologically acceptable and confers appropriate stability / osmolality to the formulation. It particularly prevents the net flow of water through cell membranes in contact with the formulation. Stabilizers are also effective as cryoprotectants during the freeze-drying (lyophilisation) process. Compounds such as glycerin are typically used for such purposes. Other suitable stabilizing agents include, but are not limited to, amino acids or proteins, salts (e.g., sodium chloride), and sugars (e.g., dextrose, trehalose, sucrose, and lactose). In some embodiments, the stabilizer is sucrose.
[0038] The term "bulking agent" refers to a chemical that provides structure to the lyophilisate or residual solid mass of pharmaceutical preparation after being lyophilized and protects it from disintegration.Crystallizable bulking agent means the bulking agent described herein that can crystallize during lyophilization.The bulking agent can be, for example, glycine.
[0039] The term "freeze-drying", also known as "lyophilization", refers to a process for obtaining a lyophilized formulation consisting of at least three main steps: 1) lowering the temperature of the product to be lyophilized below the freezing point (typically -40°C to -80°C; freezing step), 2) high pressure vacuum (typically 30 to 300 mTorr; first drying step), and 3) increasing the temperature (typically 20°C to 40°C; second drying step). Techniques for lyophilization of solutions containing antibodies are well known in the art. Many commercially available monoclonal antibody products, such as SYNAGIS™, REMICADE™, CIMZIA™, RAPTIVA™, SIMULECT™, XOLAIR™, and HERCEPTIN™, are supplied as lyophilized formulations. Lyophilized formulations are also known as "lyophilized formulations" or even "lyophilisates".
[0040] The term "vial" or "container" as used herein refers broadly to a reservoir suitable for holding the formulation described herein in liquid form or lyophilized form.Similarly, when the formulation is in lyophilized form, it holds the solvent for reconstitution.The examples of vials that can be used in the present invention include ampules, tubes, bottles, syringes (such as prefilled syringes), cartridges, or other such reservoirs that are suitable for delivering formulations to patients via injection, for example, via intravenous infusion or subcutaneous injection.
[0041] The term "solvent" as used herein refers to an aqueous solvent. The aqueous solvent may consist of water alone or may contain water plus one or more miscible solvents, and may contain dissolved solutes such as sugars, buffers, salts, or other excipients. Non-limiting aqueous solvents include water (such as water for injection), as well as saline solvent or saline buffer (such as PBS).
[0042] The term "reconstitution time" as used herein means the time required to reconstitute lyophilizate with a desired volume of solvent (e.g., water or saline buffer). Unexpectedly, a good excipient reduces the total reconstitution time by at least about 10% or more. Reconstitution time is determined by the final volume of the reconstituted product that is reconstituted. Typically, for example, an acceptable reconstitution time is considered to be within the range of 10 minutes or less per mL volume. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0043] Detailed Description of the Invention The present invention is based in part on the inventors' surprising discovery that the combination of sucrose and glycine in a buffer, more particularly in certain ratios, results in a lyophilized pharmaceutical composition containing Fab-PEG or Fab'-PEG molecules that confers long-term stability to the Fab-PEG or Fab'-PEG molecules without affecting the processability of the pharmaceutical composition. The inventors' discovery is that the pharmaceutical compositions according to the invention are stable over a period of time, particularly when stored in a lyophilized state at 2-25°C, as shown, for example, at 2-8°C and 25°C. In some embodiments, the lyophilized formulations according to the invention are also easy to reconstitute (less than 20 minutes).
[0044] In one aspect, the present invention provides a method for producing a medicament for a cellular function comprising: a. Fab-PEG or Fab'-PEG molecule at a concentration of about 50 to about 200 mg / mL; b. a buffer that maintains a pH between about 5.0 and about 7.0; c. about 1 to about 5% w / v sucrose; d. about 0.5 to about 4% w / v glycine, and e. Optionally, a surfactant The present invention provides a liquid pharmaceutical composition comprising:
[0045] In some embodiments, the Fab-PEG or Fab'-PEG molecule is preferably derived from a humanized or human antibody, which preferably specifically binds to CD40L, such as human CD40L.
[0046] In some embodiments, the Fab-PEG or Fab'-PEG molecule is a pegylated Fab or Fab' fragment as disclosed in WO 2008 / 118356 (herein incorporated in its entirety) and has a light chain variable region (LCVR) having CDR1, CDR2 and CDR3 with the amino acid sequences of SEQ ID NOs:4, 5 and 6, respectively, and a heavy chain variable region (HCVR) having CDR1, CDR2 and CDR3 with the amino acid sequences of SEQ ID NOs:1, 2 and 3, respectively. In some embodiments, the Fab-PEG or Fab'-PEG molecule has a VL chain sequence as shown in SEQ ID NO:7 and a VH chain sequence as shown in SEQ ID NO:8. In some embodiments, the Fab-PEG or Fab'-PEG molecule has a light chain sequence as shown in SEQ ID NO:9 and a heavy chain sequence as shown in SEQ ID NO:10. In some embodiments, the Fab-PEG or Fab'-PEG molecule is PEGylated at a cysteine in the modified hinge region as described in WO 2008 / 118356. In some embodiments, a maleimide group is covalently linked to one thiol group on the cysteine in the modified hinge region. In some embodiments, a lysine residue is then covalently linked to the maleimide group and a methoxypoly(ethylene glycol) polymer having a molecular weight of approximately 20 KDa is attached to each of the amine groups on the lysine residue. Thus, the total molecular weight of the entire PEG covalently linked to the monovalent Fab' can be approximately 40 KDa. An anti-CD40L Fab-PEG or Fab'-PEG molecule according to the invention can also comprise a light chain variable region comprising SEQ ID NO:7 or a sequence having at least 80% identity thereto, and / or a heavy chain variable region comprising SEQ ID NO:8 or a sequence having at least 80% identity thereto. Alternatively or additionally, an anti-CD40L Fab-PEG or Fab'-PEG molecule according to the invention may also comprise a light chain comprising SEQ ID NO:9 or a sequence having at least 80% identity thereto, and / or a heavy chain comprising SEQ ID NO:10 or a sequence having at least 80% identity thereto.
[0047] Thus, in some embodiments, the pharmaceutical composition and / or lyophilized formulation according to the invention comprises: a. comprising a CDR-H1 having the sequence defined in SEQ ID NO:1; a CDR-H2 having the sequence defined in SEQ ID NO:2; a CDR-H3 having the sequence defined in SEQ ID NO:3; a CDR-L1 having the sequence defined in SEQ ID NO:4; a CDR-L2 having the sequence defined in SEQ ID NO:5; and a CDR-L3 having the sequence defined in SEQ ID NO:6; or b. comprising a light chain variable region having the sequence defined in SEQ ID NO:7, and a heavy chain variable region having the sequence defined in SEQ ID NO:8; or c. A light chain variable region having at least 80% identity, preferably 90% identity, to the sequence defined in SEQ ID NO:7, and a heavy chain variable region having at least 80% identity, preferably 90% identity, to the sequence defined in SEQ ID NO:8; Includes Fab-PEG or Fab'-PEG molecules.
[0048] Throughout this specification, complementarity determining regions ("CDRs") are defined according to the Kabat definition (Kabat et al., (1991), 5th edition, NIH publication No. 91-3242).
[0049] In some embodiments, the Fab-PEG or Fab'-PEG molecule is present in the pharmaceutical composition at a concentration of about 50 to about 200 mg / mL, e.g., about 70 to about 150 mg / mL, e.g., about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, or about 150 mg / mL. Alternatively or additionally, the Fab-PEG or Fab'-PEG molecule is present in the liquid pharmaceutical composition in an amount expressed in grams per 100 mL (% w / v). Thus, in some embodiments, the Fab-PEG or Fab'-PEG molecules present in the pharmaceutical composition as a whole can be present in an amount of about 5 to about 20% w / v, e.g., about 7 to about 15% w / v, e.g., about 7.0, about 7.5, about 8.0, about 8.5, about 9.0, about 9.5, about 10.0, about 10.5, about 11.0, about 11.5, about 12.0, about 12.5, about 13.0, about 13.5, about 14.0, about 14.5, or about 15.0% w / v. When the pharmaceutical composition is lyophilized, the Fab-PEG or Fab'-PEG molecules are present in an amount that can be expressed in units of weight per weight (% w / w). Thus, in some embodiments, the Fab-PEG or Fab'-PEG molecules present in the lyophilisate (i.e., the lyophilized formulation) as a whole can be present in an amount of about 50 to about 80% w / w, e.g., about 55 to about 75% w / w, e.g., about 55, about 56, about 57, about 58, about 59, about 60, about 61, about 62, about 63, about 64, about 65, about 66, about 67, about 68, about 69, about 70, about 71, about 72, about 73, about 74, or about 75.0% w / w. For example, in some embodiments, the concentration of Fab-PEG or Fab'-PEG molecules in the lyophilisate is about 67.0% w / w.
[0050] The liquid pharmaceutical composition according to the present invention generally comprises a buffer that maintains a pH between about 5.0 and about 7.0. Acceptable buffers for controlling pH at a weakly acidic to neutral pH include, but are not limited to, phosphate, acetate, citrate, histidine, arginine, TRIS, and histidine buffers. "TRIS" refers to 2-amino-2-hydroxymethyl-1,3,-propanediol and any pharmacologically acceptable salts thereof. In some embodiments, the liquid pharmaceutical composition comprises a histidine buffer, such as a histidine-HCl buffer, that maintains a pH comprised between 5.0 (or about 5.0) and 7.0 (or about 7.0), such as a pH comprised between 5.0 (or about 5.0) and 6.0 (or about 6.0), such as a pH of (about) 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, or 6.0. In all of the embodiments of the present invention, unless otherwise indicated, pH values are measured at 23-25° C. and are within ±0.1 or ±0.2 pH units. In some embodiments, the histidine buffer is a buffer containing a mixture of histidine and histidine-HCl, the ratio of which is determined by the desired pH as determined by one of skill in the art, and may also be referred to herein as a histidine / histidine-HCl buffer.
[0051] In some embodiments, the buffer concentration in the liquid pharmaceutical composition is about 10 to about 100 mM. In some embodiments, the buffer concentration is about 10 to about 50 mM, e.g., about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, or about 50 mM. For example, the buffer concentration can be 20 mM or about 20 mM. When the pharmaceutical composition is lyophilized, the buffer is present in an amount that can be expressed in units of weight per weight (% w / w). In such cases, the lyophilizate contains a buffer present in an amount of about 2% to about 14% w / w or about 3 to about 14% w / w, e.g., about 2% to about 12% w / w or 3 to about 12% w / w, e.g., about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12% w / w. For example, in some embodiments, the concentration of the buffer in the lyophilizate is about 2.5-2.6% w / w, and in further embodiments, the concentration of the buffer in the lyophilizate is about 2.6-2.8% w / w.
[0052] In the context of the present invention as a whole, sucrose is present in the liquid pharmaceutical composition in an amount of about 1 to about 5% w / v, e.g., about 1.5 to about 4% w / v, or in some embodiments, in an amount of about 2 to about 4% w / v, e.g., about 2.0, about 2.25, about 2.5, about 2.75, about 3.0, about 3.25, about 3.5, about 3.75, or about 4.0% w / v. For example, the amount of sucrose can be about 2.5% w / v. When the pharmaceutical composition is lyophilized, sucrose is present in an amount that can be expressed in units of weight per weight (% w / w). In such cases, the lyophilisate comprises sucrose in an amount of about 7 to about 30% w / w, e.g., about 10 to about 25% w / w, or in some embodiments, in an amount of about 15 to 25% w / w, e.g., about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, or about 25% w / w. For example, in some embodiments, the amount of sucrose in the lyophilisate can be about 16.5 to 16.75% w / w.
[0053] In the context of the present invention as a whole, glycine is present in the liquid pharmaceutical composition in an amount of about 0.5 to about 4% w / v, e.g., about 1 to about 3% w / v, or in an amount of about 1.5 to about 3% w / v, e.g., about 1.5, about 1.75, about 2.0, about 2.25, about 2.5, about 2.75, about 3.0% w / v. In some embodiments, the glycine used according to the present invention is L-glycine. For example, the amount of glycine can be about 2.0% w / v. When the pharmaceutical composition is lyophilized, glycine is present in an amount that can be expressed in units of weight per weight (% w / w). In such cases, the lyophilisate comprises glycine in an amount of about 3.5 to about 24% w / w, e.g., about 7 to about 20% w / w or about 10 to about 20% w / w, e.g., about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20% w / w. For example, in some embodiments, the amount of glycine in the lyophilisate can be about 13.3 to 13.5% w / w.
[0054] In the context of the present disclosure as a whole, a surfactant may optionally be present in the liquid pharmaceutical composition. If present, the surfactant is, for example, a polysorbate such as PS20. The surfactant is added to the aqueous antibody molecule-containing solution at a concentration of about 0.01% to about 0.2% w / v, for example, at a concentration of about 0.02% to about 0.1% (w / v), for example, at a concentration of about 0.02, about 0.03, about 0.04, about 0.05, about 0.06, about 0.07, about 0.08, about 0.09, or about 0.1% (w / v). For example, the surfactant is PS20 and in an amount of about 0.05% w / v. When the pharmaceutical composition is lyophilized, the surfactant is present in an amount expressed in units of weight per weight (% w / w). In such cases, the lyophilisate comprises the surfactant in an amount of about 0.07-1.3% w / w, e.g., in an amount of about 0.1-0.7% w / w, e.g., in an amount of about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, or about 0.7% w / w. For example, the surfactant is PS20 and its amount in the lyophilisate can be 0.3% w / w or about 0.3% w / w.
[0055] It has been surprisingly shown by the inventors that in the context of the present invention as a whole, the weight / weight (w / w) ratio sucrose:glycine plays an important role in the performance of the lyophilisate. In some embodiments, the ratio (w / w) sucrose:glycine is about 2:3 to about 2:1. In some embodiments, the ratio (w / w) sucrose:glycine is about 3:4 to about 5:3 or about 4:5 to about 3:2. In some embodiments, the ratio (w / w) sucrose:glycine can be about 3:4, about 4:5, about 5:6, about 9:10, about 11:12, about 1:1, about 13:12, about 7:6, about 6:5, about 5:4, or about 4:3. For example, the ratio (w / w) sucrose:glycine can be about 1:1 or about 5:4. Thus, in some embodiments, as used herein, a. Fab-PEG or Fab'-PEG molecule at a concentration of about 50 to about 200 mg / mL; b. a buffer that maintains a pH between about 5.0 and about 7.0; c. sucrose and glycine in a ratio (w / w) of about 2:3 to about 2:1 sucrose:glycine, and d. Optionally, a surfactant A liquid pharmaceutical composition comprising:
[0056] In some embodiments, the liquid pharmaceutical composition comprises or consists of about 50 to about 200 mg / mL of Fab-PEG or Fab'-PEG molecule, about 10 to about 100 mM buffer (e.g., histidine buffer) at a pH of about 5.0 or about 7.0, about 1 to about 5% w / v sucrose, about 0.5 to about 4% w / v glycine, and optionally about 0.01 to about 0.2% w / v surfactant (e.g., PS20). In some embodiments, the liquid pharmaceutical composition comprises or consists of about 70 to about 150 mg / mL Fab-PEG or Fab'-PEG molecule, about 10 to about 50 mM buffer (e.g., histidine buffer) at a pH of about 5.0 to about 6.0, about 1.5 to about 4% w / v sucrose, about 1 to about 3% w / v glycine, and optionally about 0.02 to about 0.1% w / v surfactant (e.g., PS20). In some embodiments, the liquid pharmaceutical composition of the present invention comprises or consists of about 70 to about 150 mg / mL Fab-PEG or Fab'-PEG molecules, about 10 to about 50 mM buffer (e.g., histidine buffer) at a pH of about 5.0 to about 6.0, about 2 to about 4% w / v sucrose, about 1.5 to about 3% w / v glycine, and optionally about 0.02 to about 0.1% w / v surfactant (e.g., PS20). For example, a liquid pharmaceutical composition according to the present invention can comprise about 100 mg / mL Fab-PEG or Fab'-PEG molecules, about 20 mM histidine buffer maintaining a pH of about 5.5, about 2.5% w / v sucrose, about 2% w / v glycine, and about 0.05% w / v polysorbate 20. In some embodiments, a liquid pharmaceutical composition according to the present invention can comprise about 100 mg / mL of Fab-PEG or Fab'-PEG molecule, about 20 mM histidine buffer maintaining a pH at about 5.5, about 2.5% w / v sucrose, and about 2% w / v glycine.In some embodiments, the liquid pharmaceutical composition comprises or consists of about 50 to about 200 mg / mL of Fab-PEG or Fab'-PEG molecules, about 10 to about 100 mM of a buffer (e.g., histidine buffer) at a pH of about 5.0 or about 7.0, sucrose and glycine in a ratio (w / w) of about 2:3 to about 2:1, and optionally about 0.01 to about 0.2% w / v of a surfactant (e.g., PS20). In some embodiments, the liquid pharmaceutical composition comprises or consists of about 70 to about 150 mg / mL of Fab-PEG or Fab'-PEG molecules, about 10 to about 50 mM of a buffer (e.g., histidine buffer) at a pH of about 5.0 to about 6.0, sucrose and glycine in a ratio (w / w) of about 3:4 to about 5:3, and optionally about 0.02 to about 0.1% w / v of a surfactant (e.g., PS20). In some embodiments, the liquid pharmaceutical composition of the present invention comprises or consists of about 70 to about 150 mg / mL Fab-PEG or Fab'-PEG molecules, about 10 to about 50 mM buffer (e.g., histidine buffer) at a pH of about 5.0 to about 6.0, sucrose and glycine in a ratio (w / w) of about 4:5 to about 3:2, and optionally about 0.02 to about 0.1% w / v surfactant (e.g., PS20). For example, a liquid pharmaceutical composition according to the present invention can comprise about 100 mg / mL Fab-PEG or Fab'-PEG molecules, about 20 mM histidine buffer maintaining a pH of about 5.5, sucrose and glycine in a ratio (w / w) of 1:1 or about 5:4, and about 0.05% w / v polysorbate 20. In some embodiments, the liquid pharmaceutical composition according to the present invention can comprise about 100 mg / mL of Fab-PEG or Fab'-PEG molecules, about 20 mM histidine buffer maintaining a pH of about 5.5, and sucrose and glycine in a ratio (w / w) of about 1:1 or about 5:4, respectively. The present invention further describes lyophilized formulations. Techniques for lyophilization of liquid pharmaceutical compositions comprising Fab-PEG or Fab'-PEG molecules are well known in the art.
[0057] The present invention further describes a lyophilized formulation comprising about 50 to about 80% w / w Fab-PEG or Fab'-PEG molecules, about 2% to about 12% w / w or about 3 to about 14% w / w of a buffer solution maintaining a pH between about 5.0 to about 7.0, about 7 to about 30% w / w of sucrose, about 3.5 to about 24% w / w of glycine, and optionally a surfactant. In some embodiments, the lyophilized formulation (i.e., lyophilisate) comprises about 58 to about 75% w / w Fab-PEG or Fab'-PEG molecules, about 2% to about 12% w / w or about 3 to about 12% w / w of a buffer solution maintaining a pH between about 5.0 to about 7.0, about 10 to about 25% w / w of sucrose, about 7 to about 20% w / w of glycine, and optionally about 0.07 to about 1.3% w / w of a surfactant. In some embodiments, the lyophilisate comprises about 58 to about 75% w / w Fab-PEG or Fab'-PEG molecules, about 2% to about 12% w / w or about 3 to about 12% w / w of a buffer solution that maintains a pH between about 5.0 to about 7.0, about 15 to about 25% w / w of sucrose, about 10 to about 20% w / w of glycine, and optionally about 0.1 to about 0.7% w / w of a surfactant. In some embodiments, the lyophilisate comprises about 67% w / w Fab-PEG or Fab'-PEG molecules, about 2.5 to 2.6% w / w of a buffer solution that maintains a pH between about 5.0 to about 7.0, about 16.5 to 16.75% w / w of sucrose, about 13.3 to 13.5% w / w of glycine, and optionally about 0.3% w / w of a surfactant. In a further embodiment, the lyophilized formulation comprises about 67% w / w Fab-PEG or Fab'-PEG molecule, about 2.6-2.8% w / w histidine buffer maintaining a pH of about 5.5, about 16.5 and 17.5% w / w sucrose, about 13.3-13.5% w / w glycine, and 0.3-0.4% w / w polysorbate 20.
[0058] Those skilled in the art will appreciate that the total combined amount of the components in any given composition in % w / w of the formulation components will equal 100%. The phrase "buffer that maintains pH between...w / w" in the context of a lyophilized formulation according to the present invention should also be understood to refer to the pH of the starting liquid formulation from which the lyophilized formulation was derived. For example, in a lyophilized formulation comprising about 67% w / w Fab-PEG or Fab'-PEG molecules, about 2.6-2.8% w / w histidine buffer that maintains pH at about 5.5, about 16.5 and 17.5% w / w sucrose, about 13.3-13.5% w / w glycine, and 0.3-0.4% w / w polysorbate 20, the histidine buffer that maintains pH at about 5.5 may comprise about 0.3-0.4% w / w histidine and 2.3-2.4% w / w histidine-HCl.
[0059] In some embodiments, the lyophilized formulation is obtained by lyophilizing the liquid pharmaceutical composition according to the present invention in its entirety. a. Fab-PEG or Fab'-PEG molecule at a concentration of about 50 to about 200 mg / mL; b. a buffer that maintains a pH between about 5.0 and about 7.0; c. about 1 to about 5% w / v sucrose; d. about 0.5 to about 4% w / v glycine, and e. Optionally, a surfactant Also included is a lyophilized formulation obtained by lyophilizing a liquid pharmaceutical composition comprising:
[0060] In some embodiments, the lyophilized formulation is obtained by lyophilizing a liquid pharmaceutical composition comprising or consisting of Fab-PEG or Fab'-PEG molecules at about 50 to about 200 mg / mL, about 10 to about 100 mM buffer (e.g., histidine buffer) at a pH of about 5.0 to about 7.0, about 1 to about 5% w / v sucrose, about 0.5 to about 4% w / v glycine, and optionally about 0.01 to about 0.2% w / v PS20. In some embodiments, the lyophilized formulation is obtained by lyophilizing a liquid pharmaceutical composition comprising or consisting of Fab-PEG or Fab'-PEG molecules at about 70 to about 150 mg / mL, about 10 to about 50 mM buffer (e.g., histidine buffer) at a pH of about 5.0 to about 6.0, about 1.5 to about 4% w / v sucrose, about 1 to about 3% w / v glycine, and optionally about 0.02 to about 0.1% w / v PS20. In some embodiments, the lyophilized formulation is obtained by lyophilizing a liquid pharmaceutical composition comprising or consisting of about 70 to about 150 mg / mL Fab-PEG or Fab'-PEG molecules, about 10 to about 50 mM buffer (e.g., histidine buffer) at a pH of about 5.0 to about 6.0, about 2 to about 4% w / v sucrose, about 1.5 to about 3% w / v glycine, and optionally about 0.02 to about 0.1% w / v PS20. For example, the lyophilized formulation is obtained by lyophilizing a liquid pharmaceutical composition comprising about 100 mg / mL Fab-PEG or Fab'-PEG molecules, about 20 mM histidine buffer maintaining a pH of about 5.5, about 2.5% w / v sucrose, about 2% w / v glycine, and about 0.05% w / v polysorbate 20. In some embodiments, the lyophilized formulation is obtained by lyophilizing a liquid pharmaceutical composition comprising about 100 mg / mL of Fab-PEG or Fab'-PEG molecule, about 20 mM histidine buffer maintaining a pH of about 5.5, about 2.5% w / v sucrose, and about 2% w / v glycine.
[0061] The present invention further provides a method for manufacturing any of the above pharmaceutical compositions. In some embodiments, the method includes forming a mixture of Fab-PEG or Fab'-PEG molecules together with a buffer, sucrose, glycine, and a surfactant. The manufacturing step is typically carried out using conventional techniques. In some embodiments, to prepare a suitable liquid pharmaceutical composition according to the present invention, a given amount of Fab-PEG or Fab'-PEG molecules, for example, about 50 to about 200 mg / mL, is mixed with about 10 to about 100 mM buffer (e.g., histidine buffer) maintaining a pH of about 5.0 to about 7.0, about 1 to about 5% w / v sucrose, about 0.5 to about 4% w / v glycine, and optionally a surfactant. Each one of these compounds (i.e., Fab-PEG or Fab'-PEG molecules, buffer, sucrose, glycine, and optional surfactant) can be used according to the concentrations, pH, and / or ratios described above. The resulting mixture is then dispensed into vials. Variations of this process will be recognized by those of skill in the art.
[0062] The present invention further provides methods for producing any of the above lyophilized formulations (i.e., lyophilisates). In some embodiments, such methods include the steps of: 1) forming a mixture of Fab-PEG or Fab'-PEG molecules together with a buffer, sucrose, glycine, and an optional surfactant, 2) subjecting the mixture of step 1) to lyophilization, and 3) recovering the lyophilized formulation. The producing steps are carried out using conventional techniques. In some embodiments, to prepare a suitable stable formulation, 1) a predetermined amount of Fab-PEG or Fab'-PEG molecule, for example, about 50 to about 200 mg / mL, is mixed with about 10 to about 100 mM of a buffer (e.g., histidine buffer) that maintains a pH of about 5.0 to about 7.0, about 1 to about 5% w / v of sucrose, about 0.5 to about 4% w / v of glycine, and optionally about 0.01 to about 0.2% w / v of PS20, 2) the resulting mixture of step 1) is subjected to a freeze buffer, and 3) the lyophilizate is collected. Each one of the compounds (i.e., Fab-PEG or Fab'-PEG molecule, buffer, sucrose, glycine, and optional surfactant) can be used according to the concentrations, pH, and / or ratios described above. The resulting lyophilizate is then dispensed into vials. Variations of this process will be recognized by those skilled in the art.
[0063] Additional excipients for use within a liquid pharmaceutical composition or lyophilized formulation according to the present invention include, without any limitation, viscosity enhancing agents, bulking agents, stabilizers, and / or combinations thereof.
[0064] The present invention also provides a container that contains the pharmaceutical composition according to the present invention.In some embodiments, the container can be, but is not limited to, the vial, ampoule, tube, bottle, and / or syringe (e.g., pre-filled syringe) that contains the pharmaceutical composition.
[0065] In some embodiments, the container may be part of a kit-of-parts that includes one or more containers containing a liquid pharmaceutical composition or lyophilized formulation according to the invention, and a delivery device, e.g., a syringe, prefilled syringe, autoinjector, needleless device, implant, or patch, and / or other device for parenteral administration, and instructions for use.
[0066] The present invention also provides a kit-of-parts comprising the liquid pharmaceutical formulation or lyophilized formulation described above and instructions for use. In a further embodiment, the kit-of-parts comprises a liquid or lyophilized formulation according to the invention in one or more containers and instructions for use.
[0067] The invention also provides an article of manufacture for pharmaceutical or veterinary use comprising a container containing any of the liquid pharmaceutical compositions or lyophilized formulations described above. Packaging materials providing instructions for use are also described.
[0068] The lyophilized formulations provided herein, particularly single-use lyophilized formulations, are suitable for use in pharmaceutical or veterinary applications when reconstituted with a solvent. The volume of the solvent used in the reconstitution determines the concentration of the Fab-PEG or Fab'-PEG molecules in the resulting liquid pharmaceutical composition. Reconstitution with a volume of solvent less than the volume before lyophilization provides a formulation that is more concentrated than before lyophilization, and vice versa. Thus, the present invention provides a method for reconstituting the lyophilized pharmaceutical composition according to the present invention by adding a solvent. In some embodiments, the solvent is water (e.g., water for injection) or a saline buffer (e.g., PBS). The reconstitution ratio (volume of pharmaceutical composition before lyophilization to the solvent used to reconstitute the lyophilized pharmaceutical composition) can vary from about 2:1 to about 1:10, such as about 2:1, about 3:2, about 1:1, or about 1:2. Thus, as a non-limiting example, if the pre-lyophilized pharmaceutical composition comprises or consists of 100 mg / mL Fab-PEG or Fab'-PEG molecule, 20 mM histidine buffer maintaining a pH of about 5.5, 2.5% w / v sucrose, 2% w / v glycine, and 0.05% w / v polysorbate 20, and if the reconstitution ratio is 1:1, the reconstituted formulation will contain 100 mg / mL Fab-PEG or Fab'-PEG molecule, 20 mM histidine buffer maintaining a pH of about 5.5, 2.5% w / v sucrose, 2% w / v glycine, and 0.05% w / v polysorbate 20.
[0069] The present invention further describes a lyophilized formulation, characterized in that after reconstitution of the lyophilized formulation, the resulting liquid formulation comprises Fab-PEG or Fab'-PEG molecules at about 70 to about 150 mg / mL, about 10 to about 50 mM buffer (e.g., histidine buffer) at a pH of about 5.0 to about 6.0, about 2 to about 4% w / v sucrose, about 1.5 to about 3% w / v glycine, and optionally about 0.02 to about 0.1% w / v surfactant (e.g., PS20). For example, a lyophilized pharmaceutical composition after reconstitution according to the present invention may comprise about 100 mg / mL Fab-PEG or Fab'-PEG molecules, about 20 mM histidine buffer maintaining a pH of about 5.5, about 2.5% w / v sucrose, about 2% w / v glycine, and about 0.05% w / v polysorbate 20. In some embodiments, the reconstituted lyophilized pharmaceutical composition according to the present invention can comprise about 100 mg / mL of Fab-PEG or Fab'-PEG molecule, about 20 mM histidine buffer maintaining a pH of about 5.5, about 2.5% w / v of sucrose, and about 2% w / v of glycine. In some embodiments, the reconstituted lyophilized pharmaceutical composition comprises or consists of about 50 to about 200 mg / mL of Fab-PEG or Fab'-PEG molecule, about 10 to about 100 mM of buffer (e.g., histidine buffer) at about 5.0 or about 7.0 pH, sucrose and glycine in a ratio (w / w) of about 2:3 to about 2:1, and optionally about 0.01 to about 0.2% w / v of surfactant (e.g., PS20). In some embodiments, the lyophilized pharmaceutical composition after reconstitution comprises or consists of about 70 to about 150 mg / mL of Fab-PEG or Fab'-PEG molecules, about 10 to about 50 mM buffer (e.g., histidine buffer) at a pH of about 5.0 to about 6.0, sucrose and glycine in a ratio (w / w) of about 3:4 to about 5:3, and optionally about 0.02 to about 0.1% w / v of a surfactant (e.g., PS20).In some embodiments, the reconstituted lyophilized pharmaceutical composition of the present invention comprises or consists of about 70 to about 150 mg / mL Fab-PEG or Fab'-PEG molecules, about 10 to about 50 mM buffer (e.g., histidine buffer) at a pH of about 5.0 to about 6.0, sucrose and glycine in a ratio (w / w) of about 4:5 to about 3:2, and optionally about 0.02 to about 0.1% w / v surfactant (e.g., PS20). For example, the reconstituted lyophilized pharmaceutical composition of the present invention can comprise about 100 mg / mL Fab-PEG or Fab'-PEG molecules, about 20 mM histidine buffer maintaining a pH of about 5.5, sucrose and glycine in a ratio (w / w) of 1:1 or about 5:4, and about 0.05% w / v polysorbate 20. In some embodiments, a lyophilized pharmaceutical composition after reconstitution according to the present invention can comprise about 100 mg / mL of Fab-PEG or Fab'-PEG molecule, about 20 mM histidine buffer maintaining a pH of about 5.5, and sucrose and glycine in a ratio (w / w) of about 1:1 or about 5:4. In other embodiments, a lyophilized pharmaceutical composition after reconstitution according to the present invention can comprise about 70 mg / ml of Fab-PEG or Fab'-PEG molecule, about 14 mM histidine / histidine HCl buffer maintaining a pH of about 5.5, and sucrose and glycine in a ratio (w / w) of about 1:1 or about 5:4.
[0070] In some embodiments, the lyophilized formulations of the invention may be maintained for at least about 12 months to about 24 months. In some embodiments, under preferred storage conditions, prior to first use, the formulations are maintained away from bright light (preferably in the dark) at a temperature of about 2 to about 25° C., e.g., at room temperature (about 20 to 25° C.) or about 2 to 8° C. (see Examples below).
[0071] The pharmaceutical composition and / or reconstituted lyophilisate according to the present invention is for use in therapy. For example, the pharmaceutical composition or reconstituted lyophilisate according to the present invention can be used in the treatment of various disorders or diseases, such as autoimmune diseases, inflammatory diseases, cancer, neoplastic diseases, and / or neurodegenerative diseases. The present invention also provides a method for treating various disorders or diseases, such as autoimmune diseases, inflammatory diseases, cancer, neoplastic diseases, and / or neurodegenerative diseases, in a mammalian subject, comprising administering the pharmaceutical composition and / or reconstituted lyophilisate according to the present invention. In some embodiments, the pharmaceutical composition and / or reconstituted lyophilisate according to the present invention can be used in the manufacture of medicaments for the treatment of various disorders or diseases, such as autoimmune diseases, inflammatory diseases, cancer, neoplastic diseases, and / or neurodegenerative diseases.
[0072] In the context of the present invention as a whole, autoimmune or inflammatory diseases include, but are not limited to, lupus, including systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), drug-induced lupus erythematosus, or neonatal lupus, rheumatoid arthritis, ankylosing spondylitis, lupus nephritis, Sjogren's syndrome, polymyositis, dermatomyositis, temporal arteritis, ANCA-associated vasculitis, Churg-Strauss syndrome, antiphospholipid syndrome, membranous glomerular nephropathy, Goodpasture's syndrome, immunoglobulin A nephropathy, Hepatitis C syndrome, and the like. These include Noch-Schönlein purpura, chronic graft rejection, atopic dermatitis, pemphigus vulgaris, psoriasis, asthma, allergies, systemic sclerosis, multiple sclerosis, Guillain-Barré syndrome, transverse myelitis, chronic immune-mediated polyneuropathy, myasthenia gravis, Addison's disease, thyroiditis, autoimmune gastritis, pernicious anemia, celiac disease, ulcerative colitis, sarcoidosis, hemolytic anemia, idiopathic thrombocytopenic purpura, Behçet's disease, primary biliary cirrhosis, autoimmune diabetes mellitus, Lyme neuroborreliosis, and interstitial lung disease. Neurodegenerative diseases include, but are not limited to, Alzheimer's disease, Parkinson's disease, Friedreich's ataxia, Huntington's disease, amyotrophic lateral sclerosis (ALS), myasthenia gravis, multifocal motor neuropathy, primary lateral sclerosis, multiple sclerosis, spinal muscular atrophy, Kennedy's disease, and spinocerebellar degeneration. As well as conditions such as atherosclerosis, heart failure, osteoarthritis, non-alcoholic steatohepatitis, irritable bowel syndrome, Crohn's disease, diabetic complications (nephropathy, neuropathy, arteriopathy, retinopathy), asthma, cystic fibrosis, chronic obstructive airways disease, epilepsy, glaucoma, age-related macular degeneration, psychiatric disorders (anxiety, depression, psychosis), chronic fatigue syndrome, enthesopathy / tendinopathy, premature birth / in utero infections, obesity / metabolic syndrome, dermatological conditions (acne vulgaris, acne rosacea, actinic keratosis), abnormal wound healing (keloid scars), genitourinary disorders (prostatosis / prostatitis, overactive bladder).
[0073] In the context of the present invention as a whole, the pharmaceutical compositions and / or reconstituted lyophilized formulations (lyophilisates) according to the invention are for use in a method of treating an autoimmune inflammatory, neurodegenerative or neuromuscular disorder in a mammalian subject, the method comprising administering a dose of about 24 mg / kg of Fab-PEG or Fab'-PEG that specifically binds CD40L to a subject in need of such treatment about once every four weeks. In some embodiments, the lyophilized formulations according to the invention are reconstituted according to the instructions and added to a saline bag for intravenous administration.
[0074] In certain embodiments, the lyophilized formulation of the invention comprises about 67% w / w Fab-PEG or Fab'-PEG that specifically binds CD40L, about 2.6-2.8% w / w histidine / histidine HCl buffer maintaining a pH of about 5.5, about 16.5 and 17.5% w / w sucrose, about 13.3-13.5% w / w glycine, and 0.3-0.4% w / w polysorbate 20, reconstituted according to instructions for use in a method of treating an autoimmune disease such as systemic lupus erythematosus in a mammalian subject, the method comprising administering a 24 mg / kg dose of Fab-PEG or Fab'-PEG that specifically binds CD40L to a subject in need of such treatment at a frequency of about once every 4 weeks. In certain embodiments, the reconstituted lyophilized formulation of the invention is administered for at least 24 weeks, or at least 48 weeks.
[0075] In certain embodiments, the Fab-PEG or Fab'-PEG that specifically binds to CD40L is a) comprising a CDR-H1 having the sequence defined in SEQ ID NO:1; a CDR-H2 having the sequence defined in SEQ ID NO:2; a CDR-H3 having the sequence defined in SEQ ID NO:3; a CDR-L1 having the sequence defined in SEQ ID NO:4; a CDR-L2 having the sequence defined in SEQ ID NO:5; and a CDR-L3 having the sequence defined in SEQ ID NO:6; or b) comprising a light chain variable region having the sequence defined in SEQ ID NO:7, and a heavy chain variable region having the sequence defined in SEQ ID NO:8; or c) comprises a light chain variable region having at least 80% identity, preferably 90% identity, to the sequence defined in SEQ ID NO:7, and a heavy chain variable region having at least 80% identity, preferably 90% identity, to the sequence defined in SEQ ID NO:8; or d) comprises a light chain as defined in SEQ ID NO:9 and a heavy chain as defined in SEQ ID NO:10.
[0076] In some embodiments, the Fab-PEG or Fab'-PEG molecule comprises: a) comprises a maleimide group covalently linked to one thiol group in the modified hinge region; a lysine residue is covalently linked to the maleimide group; and b) A methoxypoly(ethylene glycol) polymer having a molecular weight of approximately 20 KDa is attached to each of the amine groups on the lysine residues.
[0077] In a further embodiment, the reconstituted lyophilized formulation of the present invention is for use in the method of treating autoimmune inflammatory disorder, neurodegenerative disorder, or neuromuscular disorder in combination with additional therapeutic agents.For example, the reconstituted lyophilized formulation of the present invention can be co-administered with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or therapies that target a number of proinflammatory cytokines known to be involved in the pathogenesis of immune-mediated disorders, such as TNF, IL-1, IL-6, CTLA-4, JAK, IFN (e.g., anifrolumab), or therapies that target B-cell activity, such as CD19, CD20 (e.g., rituximab), CD22, BAFF (e.g., belimumab), and BlyS / APRIL (e.g., atacicept).
[0078] In some embodiments, the lyophilized formulations of the invention have improved stability and can be readily stored at temperatures of about 2 to about 25° C., e.g., at room temperature (about 20 to 25° C.) or about 2 to 8° C. (see Examples below). Indeed, the inventors have found that a lyophilized formulation comprising about 67% w / w Fab-PEG or Fab'-PEG molecules, about 2.5 to 2.6% w / w buffer maintaining a pH between about 5.0 to about 7.0, about 16.5 to 16.75% w / w sucrose, about 13.3 to 13.5% w / w glycine, and optionally about 0.3% w / w surfactant, is stable over a period of time, particularly when stored at temperatures of about 2 to about 25° C. The formulation minimizes aggregation of the Fab-PEG or Fab'-PEG molecules, but also reduces the time for reconstitution.
[0079] The following examples are provided to further illustrate the preparation of the formulations and compositions of the present invention. The scope of the present invention should not be construed to consist solely of the following examples.
[0080] Array Description : TIFF2024542784000001.tif177159 EXAMPLES
[0081] Abbreviation DLS (Dynamic Light Scattering); SEC (Size Exclusion Chromatography); SE-HPLC (Size Exclusion High Performance Liquid Chromatography); CEX: Cation Exchange Chromatography; Suc (Sucrose); PS20 (Polysorbate 20); Gly (Glycine); Man (Mannitol); Tre (Trehalose); His (Histidine); Lac (Lactose); Cit (Citrate); Ace (Acetate); Pov (Povidone); Aggr: Aggregation; FD: freeze-drying or freeze-dried; conc: concentration; prelyo: before freeze-drying; recon: reconstitution
[0082] material The active pharmaceutical ingredient is a Fab'-PEG, designated herein as Fab1. Its light chain sequence is shown in SEQ ID NO:9, and its heavy chain sequence is shown in SEQ ID NO:10. This molecule is PEGylated at a cysteine in the modified hinge region as described in WO 2008 / 118356. A maleimide group is covalently linked to one thiol group in the cysteine in the modified hinge region; a lysine residue is covalently linked to the maleimide group; and a methoxypoly(ethylene glycol) polymer having a molecular weight of approximately 20 KDa is attached to each of the amine groups on the lysine residue. Thus, the total molecular weight of the entire PEG covalently linked to the monovalent Fab' is approximately 40 KDa. It is presented as a liquid composition in 50 mM sodium acetate, 125 mM sodium chloride, pH 5.0 (designated herein as DS) prior to formulation work.
[0083] method Reconfiguration: The lyophilisate was reconstituted using standard methods, i.e. by injecting water into the vial, and the time for the cake to completely dissolve into a clear solution was measured with a stopwatch.
[0084] Appearance (before and after reconstruction) The structural integrity of the cakes was visually checked and any defects were reported. Observations were supported by photographic materials. Appearance analysis of the reconstituted samples was performed to check color and detect visible particles. Appearance analysis was based on visual assessment.
[0085] Protein concentration: Protein concentrations were determined by standard methods by measuring absorbance at 280 nm after dilution to approximately 1 mg / mL and analyzed using a calibrated spectrophotometer. If the sample is visibly aggregated, it may be necessary to briefly centrifuge the sample to remove the precipitate and determine the concentration on the aspirated supernatant. The sample concentration is then calculated using the established extinction coefficient according to the following formula: TIFF2024542784000002.tif12128 (c = protein concentration (mg / mL); A 280 = absorbance at 280 nm; dil = dilution factor; E m = extinction coefficient (0.82 mL / mg.cm); b = path length (cm).
[0086] Protein Aggregates, High Molecular Weight Species, and Low Molecular Weight Species: SEC or SE-HPLC was used according to standard methods to separate and quantitate product-related species (e.g., low molecular weight species, aggregates, and high molecular weight species) in the reconstituted formulations. Detection and quantitation was performed by UV absorbance at 214 nm.
[0087] Acidic and basic species: CEX analysis was used to determine the charge profile according to standard methods (with fluorescence detection at emission at 340 nm and excitation at 280 nm) to provide values for total acidic and basic species.
[0088] Example 1: Preliminary Screening Formulation development began with preliminary screening studies to preselect at least buffers and stabilizers (see Table 1). Standard procedures for lyophilization were applied. Pre-lyophilized formulations contained 100 mg / mL Fab1 and were prepared by buffer exchange.
[0089] Table 1. Preliminary screening formulations TIFF2024542784000003.tif101157
[0090] Lyophilized samples were reconstituted by injecting 0.5 ml of water into the vial for formulations with Fab1 concentration of 100 mg / mL, and 1.0 ml of water into the vial for formulations with antibody concentration of 50 mg / mL.
[0091] The lyophilized formulations were evaluated by lyophilized cake appearance, which appeared to be an acceptable, white, well-formed cake without defects (photos not shown).
[0092] (Table 2) Reconstitution time and Fab1 concentration after reconstitution TIFF2024542784000004.tif116158 a. Due to volume effects of the lyophilized cake, protein concentrations were typically lower than those of the initial lyophilized formulation.
[0093] Samples were then assessed for reconstitution time and protein concentration (see Table 2).
[0094] As can be seen, there was a dramatic increase in reconstitution time between the 50 and 100 mg / mL formulations, with the reconstitution time being more pronounced for the 100 mg / mL formulation. Note that upon reconstitution with 0.5 ml of water, the solution was diluted compared to the pre-lyophilized formulation.
[0095] Protein aggregation was also determined for formulations with 100 mg / mL of antibody (see Table 3). No significant differences in protein aggregation were observed with the different formulations.
[0096] Table 3. Protein aggregation before lyophilization / after reconstitution TIFF2024542784000005.tif112128 a. No data, interference from povidone in chromatogram
[0097] Since no significant differences in protein aggregation were observed, only the reconstitution time was considered in comparing the different formulations. As already evident from the initial data review, povidone had a negative effect on the reconstitution time. Mannitol showed a positive effect on the reconstitution time. In the model, histidine as buffer and sucrose as stabilizer were suitable. The effect of the surfactant (0.01% Tween 20) was not significant.
[0098] Example 2: Optimization Screening Screening studies (Example 1) showed that the optimal pre-formulation was the sucrose / mannitol formulation, which was further evaluated for optimization. Since high pH formulations pose product stability issues related to increased acidic species, other buffers besides histidine pH 6.0 were also considered for formulation optimization and evaluated for increased acidic species (see formulations in Table 4).
[0099] Table 4. Optimized formulation TIFF2024542784000006.tif95160
[0100] All samples were evaluated for reconstitution time, protein aggregation, and acidic species (see Table 5; values at t0).
[0101] Table 5. Reconstitution time, protein concentration after reconstitution (Fab1 conc), and aggregates and acidic species before lyophilization (prelyo) / after reconstitution (after recon) TIFF2024542784000007.tif104158 a. Reconstitution times are the average of triplicate measurements. b. CEX analysis was delayed, especially for formulations 8-10, resulting in higher acidic species content.
[0102] All formulations were then evaluated for their ability to stabilize and protect the Fab-PEG product against degradation related to protein aggregation and increasing acidic species over a period of time (Table 6). Liquid samples (non-lyophilized formulations) and lyophilized samples were incubated at 2-8°C and 30°C for 4 weeks.
[0103] Table 6. Enhanced stability: protein aggregation and acidic species (after 4 weeks, T0 values reported in Table 5) TIFF2024542784000008.tif107158 a.SEC column runs explained the apparently lower content of aggregated species, decreasing the stability after 4 weeks compared to t0, however the data are still comparable between the different formulations. b. CEX analysis was delayed, especially for formulations 8-10, resulting in higher acidic species content.
[0104] For the DS formulation (100 mg / mL Fab1, 50 mM Na acetate, 125 mM NaCl, pH 5.0), a significant increase in protein aggregation and acidic species was observed after 4 weeks at 30° C., but the majority of the lyophilized products showed stability. Formulations containing higher sucrose:mannitol ratios were found to be more stable than those containing lower sucrose:mannitol ratios. In particular, the formulation containing mannitol alone showed a significant increase in protein aggregation and acidic species (Table 6, formulation 31). Formulations containing histidine buffer were found to be more stable than lactate or citrate buffers. In the liquid formulations, higher pH resulted in an accelerated increase in acidic species, especially the histidine formulation, which gave rise to more than 50% acidic species. This indicates that removal of water by lyophilization is the most important factor in stabilizing DP against the increase in acidic species.
[0105] As in Example 1, reconstitution times were shortest for formulations containing histidine buffer (Table 5).
[0106] Considering both reconstitution time and stability aspects, histidine pH 6.0 was shown to be the best choice as buffer. The sucrose:mannitol ratio was a compromise between reconstitution time (low sucrose:mannitol ratio) and stability (high sucrose:mannitol ratio). The optimal composition of the lyophilized formulation was determined as 20 mM histidine pH 6.0, 2.5% sucrose, 2.5% mannitol, 100 mg / mL antibody molecules. The reconstitution time of this formulation was less than 5 minutes (reconstituted with 0.5 mL water) and it was stable against the increase of acidic species even after 4 weeks at 30°C.
[0107] Example 3: Further optimization studies A key issue with the molecule is its stability, especially with respect to hydrolysis and ring opening of the succinimide PEG linker, which leads to an increase in the level of acidic species. The hydrolysis of the linker is strongly dependent on pH. With increasing pH, hydrolysis is accelerated. The rate of increase in acidic species was reduced in the lyophilized formulation. Meanwhile, it was recommended to reduce the pH of the lyophilized formulation and to identify further optimized formulation candidates in order to minimize the hydrolysis of the linker during formulation preparation and after reconstitution. In this regard, further formulations containing glycine instead of mannitol were evaluated at different pH (Table 7).
[0108] Table 7. Composition of further formulations TIFF2024542784000009.tif50158A1 and B1: freeze-drying by sublimation at -20°C; A2 and B2: freeze-drying by sublimation at -5°C
[0109] Table 8. Reconstitution time and protein concentration after reconstitution (formulations were reconstituted with water to a final volume of 0.5 mL) TIFF2024542784000010.tif70160
[0110] Table 9. Aggregated and acidic species TIFF2024542784000011.tif72160
[0111] Residual moisture was 1-2% in the lyophilized preparations obtained by sublimation at -20°C and less than 1% in the lyophilized preparations obtained by sublimation at -5°C (data not shown).
[0112] Reconstitution times were less than 10 minutes or even less than 3 minutes for certain formulations (Table 8). After 4 weeks of storage at 2-8°C, and especially at 40°C, reconstitution times increased significantly, especially for lyophilized formulations obtained by a freeze-drying cycle with sublimation at -5°C.
[0113] For formulations containing 2.5% sucrose and 2.5% glycine, the osmolality was greater than 450 mOsm and the pH of the reconstituted formulation was 0.2–0.5 higher than the target pH (data not shown).
[0114] Aggregation levels were slightly higher in the lactic acid formulation (Table 9), especially after 4 weeks at 40° C. Furthermore, a significant increase in the levels of acidic species was observed in the lactic acid formulation (Table 9).
[0115] Glycine did not crystallize in formulations containing only 1.5% glycine. However, partial crystallization of glycine was observed in formulations with 2.0% glycine, especially in formulations with 2.5% glycine (data not shown). Higher sublimation temperatures did not result in higher contents of crystalline glycine. Glycine crystallized as the β-polymorph, which is the least stable polymorphic form of glycine.
[0116] 100 mg / mL Fab1 in 20 mM histidine pH 6.0, 2.5% sucrose, 2.0% glycine, 0.05% Tween 20 was considered as a potential alternative to the lyophilized formulation of the sucrose / mannitol formulation identified in Examples 1 and 2. The sucrose / glycine lyophilized formulation also showed good reconstitution and stability characteristics. However, the osmolality of this formulation was higher than that of the sucrose / mannitol formulation.
[0117] Evaluation of buffer composition and buffer pH suggested that a histidine buffer at pH 5.5 was the best choice for the Fab1 lyophilized formulation.
[0118] Example 4: Long-term stability study With increasing pH, there is a risk of accelerating hydrolysis. In addition, in Example 2, it was shown that pH has a dramatic effect on the increase of acidic species. Furthermore, as shown in Figure 3, partial crystallization of glycine was observed in the formulations with 2.0% glycine, especially in the formulations with 2.5% glycine. Therefore, all the most preferred formulations identified in the previous examples were evaluated at a lower pH, i.e., pH 5.5 instead of pH 6.0 (see Table 10).
[0119] Table 10: Composition of the formulation TIFF2024542784000012.tif23158
[0120] The lyophilisate appeared to be an acceptable, white, well-formed cake without defects (photos not shown). After reconstitution and up to 2 months after the start of the stability study, the formulation appeared to be a colourless liquid with a slight milky luminescence and no visible particles. After reconstitution and 6-12 months after the start of the stability study, the formulation appeared to be a slightly yellow liquid with a slight milky luminescence and no visible particles.
[0121] Table 11. Reconstitution time over time TIFF2024542784000013.tif8416025℃ / 60%RH; 30℃ / 65%RH and 40℃ / 75%RH
[0122] Table 12. Aggregation over time (SE-HPLC) TIFF2024542784000014.tif88160
[0123] Table 13. Low molecular weight species over time (SE-HPLC) TIFF2024542784000015.tif88160
[0124] Table 14. Total acidic species over time TIFF2024542784000016.tif84160
[0125] Table 15. Total basic species over time TIFF2024542784000017.tif84160
[0126] The three formulations underwent six months of stability testing (see Tables 11-15). Based on the six-month stability data, formulation K was selected and continued for an additional six months of stability testing. The selected formulation surprisingly demonstrated the most consistent and shortest reconstitution time, the best stability profile against aggregation (SE-HPLC and DLS), and good stability against the increase of acidic species (see Tables 11-15).
[0127] Formulation I was not selected due to its higher content of large aggregates than polysorbate-containing formulations J and K (data not shown). Formulation J was not selected due to its higher variability in reconstitution time compared to formulation K.
[0128] References TIFF2024542784000018.tif68153
[0129] Further aspects of the present invention: 1. a. a Fab-PEG or Fab'-PEG molecule at a concentration of about 50 to about 200 mg / mL; b. a buffer that maintains a pH between about 5.0 and about 7.0; c. about 1 to about 5% w / v sucrose; d. about 0.5 to about 4% w / v glycine, and e. Optionally, a surfactant 13. A liquid pharmaceutical composition comprising: 2. A lyophilized formulation obtained by freeze-drying the pharmaceutical composition according to claim 1. 3. a. about 50 to about 80% w / w Fab-PEG or Fab'-PEG molecules; b. about 3 to about 14% w / w buffer that maintains a pH between about 5.0 and about 7.0; c. about 7 to about 30% w / w sucrose; d. about 3.5 to about 24% w / w glycine, and e. Optionally, a surfactant 13. A lyophilized formulation comprising: 4. The liquid pharmaceutical composition of claim 1, or the lyophilized formulation of claim 2 or claim 3, wherein the Fab-PEG or Fab'-PEG molecule is derived from a humanized or human antibody. 5. A liquid pharmaceutical composition according to claim 1 or claim 4, or a lyophilized formulation according to any one of claims 2 to 4, wherein the Fab-PEG or Fab'-PEG molecule specifically binds to CD40L. 6. The Fab-PEG or Fab'-PEG molecule is a. comprises a CDR-H1 having the sequence defined in SEQ ID NO:1; a CDR-H2 having the sequence defined in SEQ ID NO:2; a CDR-H3 having the sequence defined in SEQ ID NO:3; a CDR-L1 having the sequence defined in SEQ ID NO:4; a CDR-L2 having the sequence defined in SEQ ID NO:5; and a CDR-L3 having the sequence defined in SEQ ID NO:6; or b. comprising a light chain variable region having the sequence defined in SEQ ID NO:7, and a heavy chain variable region having the sequence defined in SEQ ID NO:8; or c. A light chain variable region having at least 80% identity, preferably 90% identity, to the sequence defined in SEQ ID NO:7, and a heavy chain variable region having at least 80% identity, preferably 90% identity, to the sequence defined in SEQ ID NO:8; A liquid pharmaceutical composition according to any one of claims 1 and 4 to 5, or a lyophilized formulation according to any one of claims 2 to 5. 7. The Fab-PEG or Fab'-PEG molecule is a) having a maleimide group covalently linked to one thiol group in a modified hinge region; a lysine residue is covalently linked to the maleimide group; and b) a methoxypoly(ethylene glycol) polymer having a molecular weight of approximately 20 KDa is attached to each of the amine groups on the lysine residues; 7. The liquid pharmaceutical composition or lyophilized formulation of claim 6. 8. The liquid pharmaceutical composition of any one of claims 1 and 4 to 7, or the lyophilized formulation of any one of claims 2 to 7, wherein the buffer is a histidine buffer. 9. The liquid pharmaceutical composition according to any one of claims 1 and 4 to 8, or the lyophilized preparation according to any one of claims 2 to 8, wherein the concentration of the buffer is about 10 to about 50 mM. 10. The liquid pharmaceutical composition of any one of claims 1 and 4 to 8, or the lyophilized formulation of any one of claims 2 to 8, wherein the surfactant is in an amount of about 0.01 to about 0.2%. 11. The liquid pharmaceutical composition of any one of claims 1 and 4-10, or the lyophilized formulation of any one of claims 2-10, wherein the optional surfactant is a polysorbate. 12. The liquid pharmaceutical composition or lyophilized formulation of claim 11, wherein the polysorbate is PS20. 13. A liquid pharmaceutical composition according to any one of claims 1 and 4 to 12, or a lyophilized formulation according to any one of claims 2 to 121, wherein the ratio of sucrose:glycine (w / w) is 2:3 to 2:1 or about 2:3 to about 2:1. 14. The liquid pharmaceutical composition of any one of claims 1 and 4-13, comprising about 100 mg / mL Fab-PEG or Fab'-PEG molecule, about 20 mM buffer maintaining a pH of about 5.5, about 2.5% w / v sucrose, about 2% w / v glycine, and optionally about 0.05% w / v PS20. 15. The lyophilized formulation of any one of claims 2 to 13, comprising about 67% w / w Fab-PEG or Fab'-PEG molecule, about 2.5 to 2.6% w / w buffer maintaining a pH between about 5.0 to about 7.0, about 16.5 to 16.75% w / w sucrose, about 13.3 to 13.5% w / w glycine, and optionally about 0.3% w / w surfactant. 16. The following steps: a. forming a mixture of Fab-PEG or Fab'-PEG molecules with a buffer, sucrose, glycine, and an optional surfactant to obtain a pharmaceutical composition; and b. subjecting the mixture of step a. to lyophilization; and c. Recovering the lyophilized formulation 16. A method for producing the freeze-dried formulation according to any one of claims 2 to 13 and 15, comprising: 17. A method for reconstituting a lyophilized formulation according to any one of claims 2 to 13 and 15 to 16 by adding a solvent, wherein the solvent can be water or a saline buffer. 18. An article of manufacture comprising a container containing a liquid pharmaceutical composition according to any one of claims 1 and 4-14 or a lyophilized formulation according to any one of claims 2-13 and 15-17.
Claims
1. a. Fab-PEG or Fab'-PEG molecules at a concentration of about 50 to about 200 mg / mL; b. a buffer that maintains a pH between about 5.0 and about 7.0; c. about 1 to about 5% w / v sucrose; d. about 0.5 to about 4% w / v glycine, and e. Optionally, a surfactant 13. A liquid pharmaceutical composition comprising:
2. A lyophilized formulation obtained by freeze-drying the pharmaceutical composition of claim 1.
3. a. about 50 to about 80% w / w Fab-PEG or Fab'-PEG molecules; b. about 2 to about 14% w / w buffer that maintains a pH between about 5.0 and about 7.0; c. about 7 to about 30% w / w sucrose; d. about 3.5 to about 24% w / w glycine, and e. Optionally, a surfactant 13. A lyophilized formulation comprising:
4. The liquid pharmaceutical composition of claim 1, or the lyophilized formulation of claim 2 or claim 3, wherein the Fab-PEG or Fab'-PEG molecule is derived from a humanized or human antibody.
5. The liquid pharmaceutical composition of claim 1 or claim 4, or the lyophilized formulation of any one of claims 2 to 4, wherein the Fab-PEG or Fab'-PEG molecule specifically binds to CD40L.
6. The Fab-PEG or Fab'-PEG molecule is a. comprises a CDR-H1 having the sequence defined in SEQ ID NO:1; a CDR-H2 having the sequence defined in SEQ ID NO:2; a CDR-H3 having the sequence defined in SEQ ID NO:3; a CDR-L1 having the sequence defined in SEQ ID NO:4; a CDR-L2 having the sequence defined in SEQ ID NO:5; and a CDR-L3 having the sequence defined in SEQ ID NO:6; or b. a light chain variable region having the sequence defined in SEQ ID NO:7, and a heavy chain variable region having the sequence defined in SEQ ID NO:8; or c. A light chain variable region having at least 80% identity, preferably 90% identity, to the sequence defined in SEQ ID NO: 7, and a heavy chain variable region having at least 80% identity, preferably 90% identity, to the sequence defined in SEQ ID NO: 8; A liquid pharmaceutical composition according to any one of claims 1 and 4 to 5, or a lyophilized formulation according to any one of claims 2 to 5.
7. The Fab-PEG or Fab'-PEG molecule is a) having a maleimide group covalently linked to one thiol group in a modified hinge region; a lysine residue is covalently linked to the maleimide group; and b) a methoxypoly(ethylene glycol) polymer having a molecular weight of approximately 20 KDa is attached to each of the amine groups on the lysine residues; 7. The liquid pharmaceutical composition or lyophilized formulation of claim 6.
8. The liquid pharmaceutical composition of any one of claims 1 and 4 to 7, or the lyophilized formulation of any one of claims 2 to 7, wherein the buffer is a histidine buffer.
9. The liquid pharmaceutical composition of any one of claims 1 and 4-8, wherein the concentration of the buffer is from about 10 to about 50 mM.
10. The liquid pharmaceutical composition of any one of claims 1 and 4-9, wherein the surfactant is in an amount of about 0.01 to about 0.2% w / v.
11. The liquid pharmaceutical composition of any one of claims 1 and 4 to 10, or the lyophilized formulation of any one of claims 2 to 8, wherein the optional surfactant is a polysorbate.
12. 12. The liquid pharmaceutical composition or lyophilized formulation of claim 11, wherein the polysorbate is PS20.
13. The liquid pharmaceutical composition of any one of claims 1 and 4 to 12, or the lyophilized formulation of any one of claims 2 to 8 and 11 to 12, wherein the ratio of sucrose:glycine (w / w) is from 2:3 to 2:1 or from about 2:3 to about 2:
1.
14. 14. The liquid pharmaceutical composition of any one of claims 1 and 4-13, comprising about 100 mg / mL of Fab-PEG or Fab'-PEG molecule, about 20 mM buffer maintaining a pH of about 5.5, about 2.5% w / v sucrose, about 2% w / v glycine, and optionally about 0.05% w / v PS20.
15. 14. The lyophilized formulation of any one of claims 2-8 and 11-13, comprising about 67% w / w Fab-PEG or Fab'-PEG molecule, about 2.6-2.8% w / w buffer maintaining a pH between about 5.0 and about 7.0, about 16.5-16.75% w / w sucrose, about 13.3-13.5% w / w glycine, and optionally about 0.3% w / w surfactant.
16. The following steps: a. forming a mixture of Fab-PEG or Fab'-PEG molecules with a buffer, sucrose, glycine, and an optional surfactant to obtain a pharmaceutical composition; and b. subjecting the mixture of step a. to lyophilization; and c. Recovering the lyophilized preparation 16. A method for making the lyophilized formulation of any one of claims 2 to 8 and 11 to 13 and 15, comprising:
17. A method for reconstituting a lyophilized formulation according to any one of claims 2 to 8 and 11 to 13 and 15 or a lyophilized formulation obtained by the method according to claim 16, by adding a solvent, wherein the solvent can be water or a saline buffer.
18. 17. An article of manufacture comprising a container containing a liquid pharmaceutical composition according to any one of claims 1 and 4 to 14 or a lyophilized formulation according to any one of claims 2 to 8 and 11 to 13 and 15.
Citation Information
Patent Citations
Binding proteins that specifically bind to CD154, including antibodies, antibody derivatives, and antibody fragments, and their use.
JP2010521967A
Method for reducing the reconstitution time of spray-dried protein formulations
JP2021502990A
Treatment of autoimmune disorders with CD154 antibodies
WO2016119909A1
